Cosmo Pharmaceuticals N.V./€COPN
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Cosmo Pharmaceuticals N.V.
Cosmo Pharmaceuticals N.V. is a specialty pharmaceutical company headquartered in Dublin, Ireland, with a focus on developing and manufacturing treatments for gastrointestinal diseases, specifically targeting the large intestine. The company's core products include therapies for ulcerative colitis, colon infections, and related areas. Cosmo's notable products, such as Lialda/Mezavant and Eleview, highlight its focus on advanced treatments that enhance colonic drug delivery and endoscopic visualization. The company has strategically concentrated its research and development to specialize in its therapeutic areas, leveraging its proprietary Methacrylate-Copolymer technology. Cosmo Pharmaceuticals also engages in partnerships to extend its market reach and continues to expand its influence globally through strategic collaborations and licensing agreements.
- Ticker
- €COPN
- Sector
- Health
- Primary listing
- XGAT
- Employees
- 365
- Headquarters
- Dublin, Ireland
COPN Metrics
BasicAdvanced
€1.1B
-
-€0.38
1.48
€2.10
3.39%
Price and volume
Market cap
€1.1B
Beta
1.48
52-week high
€142.00
52-week low
€55.00
Average daily volume
35K
Dividend rate
€2.10
Financial strength
Current ratio
10.662
Quick ratio
9.836
Long term debt to equity
0.006
Total debt to equity
0.008
Interest coverage (TTM)
-65.87%
Profitability
EBITDA (TTM)
1.204
Gross margin (TTM)
45.51%
Net profit margin (TTM)
-6.19%
Operating margin (TTM)
-10.84%
Effective tax rate (TTM)
-53.39%
Revenue per employee (TTM)
€280,000
Management effectiveness
Return on assets (TTM)
-1.07%
Return on equity (TTM)
-1.19%
Valuation
Price to revenue (TTM)
9.949
Price to book
1.73
Price to tangible book (TTM)
4.45
Price to free cash flow (TTM)
-39.307
Free cash flow yield (TTM)
-2.54%
Free cash flow per share (TTM)
-1.575
Dividend yield (TTM)
3.39%
Forward dividend yield
3.39%
Growth
Revenue change (TTM)
-43.66%
Earnings per share change (TTM)
-110.49%
3-year revenue growth (CAGR)
-0.50%
10-year revenue growth (CAGR)
3.57%
3-year earnings per share growth (CAGR)
-16.78%
10-year earnings per share growth (CAGR)
-8.60%
3-year dividend per share growth (CAGR)
25.99%
10-year dividend per share growth (CAGR)
4.14%
What the Analysts think about COPN
Analyst ratings (Buy, Hold, Sell) for Cosmo Pharmaceuticals N.V. stock.
Analyst projections of the future price of Cosmo Pharmaceuticals N.V. stock.
Bulls say / Bears say
Recurring revenue grew 18% in H1 2026 and made up almost all revenue, with Winlevi up 38%, Lialda 35% and CDMO 14%. That spread of growth gives Cosmo several commercial engines rather than relying on one product. (Cosmo Pharmaceuticals)
Cosmo’s Phase II rifamycin gel trial reported remission in 46.2% of patients versus 14.3% on placebo, meeting its primary endpoint. If later development confirms the result, it could add a new treatment to the company’s gastrointestinal portfolio. (Quartr)
Cosmo finished H1 with €205.1 million in cash, cash equivalents and investments and no financial debt. That gives it room to fund its pipeline and commercial expansion without immediate pressure to borrow. (Cosmo Pharmaceuticals)
Despite recurring sales growth, H1 total revenue fell year on year and the operating loss widened, while EBITDA moved slightly below break-even. This shows that sales growth has not yet translated into stronger operating performance. (Cosmo Pharmaceuticals)
A July valuation snapshot put Cosmo’s price-to-sales ratio at 10.8 times, against 3.9 times for the broader European pharmaceuticals sector, while the company was loss-making. That premium leaves less room for disappointment if growth or profitability falls short. (Simply Wall St)
The positive rifamycin result came from a Phase II study whose primary analysis covered 60 patients, out of 76 enrolled. The small early-stage dataset still needs confirmation in further development before it can establish a commercial product. (StockTitan)
Data summarised monthly by Lightyear AI. Last updated on 29 Oct 2026.
COPN Financial Performance
Revenues and expenses
COPN Earnings Performance
Company profitability
Upcoming events
No upcoming events
Funds containing COPN
Fund name | Fund size | €COPN weighting |
|---|---|---|
Xtrackers MSCI Europe Small Cap£XXSC | $3.6B | 0.04% |
Xtrackers MSCI Europe Small Cap€DX2J | $3.6B | 0.04% |
Xtrackers MSCI World Small Cap$XSWC | $183M | 0.00% |
SPDR MSCI All Country World IM€SPYI | $7.7B | 0.00% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.